A multicentre prospective observational study to investigate the prevalence and short-term impact of frailty, multi-morbidity and sarcopenia in chronic limb threatening ischaemia (CLTI) The FraiLTI - (Frailty in chronic Limb Threatening Ischaemia) Study

Ashwin Sivaharan[1], Blaise Hickson[2], Tamer El-Sayed[1], Lauren Shelmerdine[1], Sai Wunnava[1], Bence Baljer[1], Dilraj Bhullar[1], Craig I Nesbitt[1], Miles D Witham[3], Sandip Nandhra[1,4]

Author affiliations:

1. Northern Vascular Centre, Freeman Hospital, Freeman Rd, High Heaton, Newcastle upon Tyne, NE7 7DN
2. The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH
3. AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, 3rd Floor Biomedical Research Building, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL
4. Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Baddiley-Clark Building, Newcastle upon Tyne, NE2 4AX

Funding:

National Institute for Health Research (NIHR)

Newcastle Hospital Charities

Corresponding Author:

Mr Ashwin Sivaharan (a.sivaharan@nhs.net)

Northern Vascular Centre, Freeman Hospital, Freeman Rd, High Heaton, Newcastle upon Tyne, NE7 7DN

Category: Observational study

Keywords:

Chronic limb threatening ischaemia (CLTI), frailty, sarcopenia, multi-morbidity, anaemia

Word Count

Abstract: 292

Main text: 2351

Collaborators

Newcastle upon Tyne Hospitals NHS Foundation Trust

- Mr Mohammed Fageer
- Miss Rana Khalil (0000-0002-9383-2986)
- Mr Lawrence Ugwumba

South Tees Hospitals NHS Foundation Trust

- Miss Fatima Mannan

University Hospitals Birmingham NHS Foundation Trust

- Mr Hosaam Nasr
- Mr Arooj Syed (0000-0002-1951-2036)
- Miss Emma Valums
- Miss Sarah Harley
- Mr Clive Allen

NHS Lothian

- Mr Andrew Tambyraja (0000-0002-9393-6291)
- Miss Sharon Y M Chan

University Hospitals of Leicester NHS Trust

- Professor Athanasios Saratzis (0000-0002-3399-094X)
- Mr John Houghton (0000-0002-9159-5307)
- Professor Robert Sayers (0000-0002-6889-4659)
- Professor Matthew J Bown (0000-0002-6180-3611)
- Mr Badri Vijaynagar

Hull University Teaching Hospitals NHS Trust

- Professor Ian Chetter (0000-0002-2566-6859)
- Miss Louise Hitchman (0000-0001-9681-6749)
- Mr Abduraheem Mohamed (0000-0002-8892-3293)
- Mr Arthur Lim (0000-0003-0011-1336)

Abstract

Background

CLTI is a is a life and limb threatening condition that is associated with a gradual overall decline in health that is under explored. We aim to measure the prevalence of correlated conditions (frailty, sarcopenia and anaemia) in patients with CLTI to assess their ability to perform activities of daily living (ADLs) alongside multimorbidity, polypharmacy and clinical outcomes.

Methods

FraiLTI is a multi-centre, prospective, observational study, funded by the National Institute for Health Research (NIHR) and supported by the Vascular and Endovascular Research (VERN). All dedicated vascular centres were eligible to participate. Ethical approval (21/PR/0750) was granted on 13/07/2021.

Primary outcome was identification of prevalence rates of frailty, sarcopenia and anaemia. Secondary outcomes included prevalence of polypharmacy and multimorbidity. Analyses included associations between frailty and sarcopenia, with clinical outcomes.

Results

By the Rockwood Clinical Frailty Scale, 43 (51.8%) patients were frail. By grip strength, 27 (33.3%) patients were sarcopenic. We found that 43 (53.8%) of patients were anaemic, with an overwhelming majority (92.1%) having normocytic anaemia. Multimorbidity was seen in 57 (67.9%) patients and 67 (79.8%) patients met the definition of polypharmacy.

Patients who were frail, were more likely to require a walking aid ($p<0.001$), be on more medications ($p=0.027$), have more co-morbidities ($p=0.002$), more likely to be diabetic ($p=0.016$), be sarcopenic ($p=0.018$), fail the walk speed test ($p=0.040$) and self-report low activity ($p<0.001$). Patients who were considered sarcopenic by grip strength tended to be older ($p=0.031$), have more co-morbidities ($p=0.049$), and were more likely to be anaemic ($p=0.004$).

Conclusion

This study shows that frailty, sarcopenia and anaemia are highly prevalent in those with CLTI. There also appears to be an important interaction between sarcopenia and anaemia, but not frailty and anaemia. The management of CLTI patients extends beyond revascularisation alone.

Introduction

Chronic Limb Threatening Ischaemia (CLTI) is a patient-clinician shared, James Lind Alliance (JLA) priority for vascular research,[1] not least because of the high risk to life with 1-year mortality rate of up to 40%, risk of limb loss, but also the impact to patients' day to day life. Patients with CLTI often have many associated conditions that might worsen outcomes; many are frail and have sarcopenia.

Frailty is defined as an age-related multisystem decline that leaves patients vulnerable to stressors such as illness, trauma, or surgery,[2] and is related to sarcopenia, nutritional deficiencies, hormonal changes and increased systemic inflammation.[3,4] Frailty has been associated with worse outcomes in a wide range of surgical disciplines[5,6], including vascular surgery.[7,8]

Meanwhile, sarcopenia is a distinct, but related concept, that describes skeletal muscle dysfunction and loss of functional strength, that comes alongside aging and frailty[9]. It has been associated with worse survival following endovascular surgery,[10] and also surgical revascularisation.[11]

Multimorbidity (multiple long-term conditions) may also be a contributing factor to outcomes in this population, both with respect to cardiovascular and non-cardiovascular conditions and has been reliably associated with poorer outcomes in multiple surgical subspecialities.[12] There is also retrospective data that suggests that anaemia, a potential marker of overall health state, is associated with worse outcomes in lower limb bypass patients.[13]

FraiLTI (Frailty in chronic Limb Threatening Ischaemia) is a UK multi-centre prospective observational study. The aim is to evaluate the prevalence and any associated impact of frailty, sarcopenia, multi-morbidity polypharmacy and anaemia on outcomes following vascular intervention for CLTI.

Methods

This multicentre, prospective observational study was conducted in UK Vascular Centres, led by a Newcastle University based Principal Investigator team and supported by the Vascular and

Endovascular Research Network (VERN). Funding was awarded by the National Institute of Health Research Biomedical Research Centre (NIHR-BRC) and the Newcastle Hospitals Charity.

Full ethical approval (21/PR/0750) was granted on 13/07/2021. The study is registered on the ISRCTN and the manuscript has been prepared as per the STROBE (Strengthening the reporting of observational studies in epidemiology) guidelines for the reporting of observational studies.[14]

All patients admitted to UK vascular centres, with CLTI[15] were invited to participate in the study across six sites. Patients were excluded if they were younger than 18 years, pregnant, or unable to consent to participation.

Study Outcomes

The primary outcome of the study is to establish the prevalence of frailty (Rockwood's Clinical Frailty Scale (CFS)), sarcopenia (by grip strength), and anaemia.

Secondary outcomes were low walk speed, low physical activity, multi-morbidity and polypharmacy. We also explored any associations between these conditions and clinical outcomes for CLTI, including mortality, major adverse limb events (MALEs), major adverse cardiovascular events (MACE), readmissions, reinterventions. complications and discharge destination. The published full protocol[16] contains further details.

Definitions

A Rockwood CFS of ≥5 was considered frail. Grip strength of <27kg for men and <16kg for women was diagnostic of sarcopenia. Multi-morbidity was defined as ≥2 long-term health conditions and polypharmacy was defined as ≥5 medications, with excessive polypharmacy defined as ≥10 medications).

Low physical activity was measured using four activity questions used in the English Longitudinal Study of Ageing.[17] The methodology used to diagnose low physical activity based on these questions has previously been published.[18]

A low walk speed was diagnosed if the speed was <0.8m/s was noted on a 4m walk test. If the patient was unable to complete the test, this was considered diagnostic of low walk speed.

Data collection

Anonymised data included patient demographics, previous treatments, and hospital admissions from the past six months. The research teams gathered this information prospectively using both electronic and paper-based hospital records. The data was then entered into a custom-built, secure, electronic database, hosted on the Newcastle Joint Research Office's Research Electronic Data Capture (REDCap) platform.

The following conditions were documented based on the patients' medical histories: ischaemic heart disease or previous myocardial infarction, atrial fibrillation, hypertension, cerebrovascular diseases (such as ischaemic stroke, haemorrhagic stroke, or transient ischaemic attack), end-stage renal failure requiring dialysis, and chronic obstructive pulmonary disease. Pre-operative medications were noted from pre-assessment clinic records.

Routine clinical laboratory results (including haemoglobin, white cell count, albumin, creatinine, eGFR, C-reactive protein, and HbA1c) were also collected, along with height and weight measurements.

Data analysis

Statistical analysis was performed using R version 4.2.3 (R Foundation for Statistical Computing, Vienna, Austria). Descriptive proportional data is presented as number (percentage, 95% confidence interval (CI), calculated using the exact binomial test). Continuous data is presented as mean (SD), and hypothesis testing was performed with t-tests, Mann Whitney u-tests. Proportional comparisons were performed with Fisher’s exact tests, where data was in a 2x2 contingency table, and chi squared tests, for the remainder of cases. A p-value <0.05 was considered statistically significant for single comparisons. Log rank tests are reported to compare the overall mortality.

Results

There were 84 patients recruited between October 2021 to October 2022. 54 (64%) were male, 30 (35.7%) were female. The mean weight was 78.8kg (SD 20.4), and height was 170cm (SD 9.8). 20 (24%) patients were current smokers, 47 (57%) were ex-smokers, and 16 (19%) were never-smokers. Demographics, co-morbidities and social factors are summarised in Table 1.

Primary outcomes

Using the Rockwood CFS, 43 patients (51.8%, CI 40.0% - 62.2%) were frail and for sarcopenia, 27 (33.3%, CI 23.2% – 44.7%) had reduced grip strength (3 missing data points).

For patients for which there was data on haemoglobin (80/84), 43 (53.8%, CI 42.2% - 65.0%) were anaemic. The overwhelming majority of the anaemic patients had normocytic anaemia 35/38 (92.1%, CI 78.6% - 98.3%), 2 microcytic (5.3%, CI 0.1% - 17.8%), and 1 macrocytic (2.6%, CI 0.0% - 13.8%).

For patients who were considered frail, 19/43 (46.3%, CI 29.1% - 60.1%) were sarcopenic by grip strength and 26/43 (63.4%, CI 44.4% - 75.0%) were anaemic.

Secondary outcomes

Low walk speed (<0.8m/s) or failure of the 4m walk speed test was observed in 32 (38.1%, CI 27.7% - 49.3%) patients. The self-reported physical activity index suggested that 56 patients (67.5%, CI 56.3% - 77.3%) were classified as having low activity. Multimorbidity was seen in 57 (67.9%, CI 56.8% - 77.6%) patients and 67 (79.8%, CI 69.6% - 87.7%) patients met the definition of polypharmacy (with excessive polypharmacy seen in 36 (42.9%, CI 32.1% - 54.1%) patients). Figure 1 shows a bar chart that summarises the prevalence of frailty, sarcopenia, anaemia, multimorbidity and polypharmacy.

Clinical course

64/81 (79.0%, CI 68.5% - 87.3%) of patients in the cohort underwent revascularisation, 36 (57.1%, CI 43.2% - 68.6%) endovascular, 27 (42.9%, CI 29.9% - 55.2%) open or hybrid. Of those 17 (21.0%, CI 12.7% - 31.4%) patients that did not undergo revascularisation, 5 (29.4%, CI 10.3% - 56.0%)

underwent primary amputation, and 12 (70.6%, CI 44.0 – 89.7%) underwent a conservative or palliative approach. Figure 2 shows a flowchart summarising this.

Complications

During the study, there were 3 (3.7%, CI 0.8% - 10.4%) MACEs, 2 (2.5%, CI 0.3% - 8.6%) respiratory complications, 5 (6.2%, CI 2.0% - 13.8%) wound complications and 6 (7.4%, CI 2.8% - 15.4%) MALEs. 29 (34.5%, CI 24.5% - 45.7%) patients in the study had at least one readmission while in the study.

Number of reinterventions

When it came to reintervention done within 90 days, there were 4 (4.9%, CI 1.2% – 12.2%) open/ hybrid interventions, 6 (7.4%, CI 2.8% – 15.4%) endovascular interventions, 2 (2.5%, CI 0.3% - 8.6%), wound-related procedures and 6 (7.4%, CI 2.8% – 15.4%)) foot debridements/ minor amputations.

Survival analysis

90-day amputation free survival in the whole cohort was 96%. There was no significant difference in mortality when groups were split by frailty (p=0.08), sarcopenia (p=0.06), or anaemia (p=0.04).

Relationships between frailty, sarcopenia, anaemia and clinical factors

Patients who were considered frail as per the CFS, were more likely to require a walking aid (p<0.001), be on more medications (p=0.027), have more co-morbidities (p=0.002), more likely to be diabetic (p=0.016), be sarcopenic by grip strength (p=0.018), fail the walk speed test (p=0.040) and self-report low activity (p<0.001). There were no significant correlations found between the presence of frailty and the complication rate, readmission rates or the number and type of reinterventions. These results are summarised in Table 2.

Patients who were considered sarcopenic by grip strength tended to be older (p=0.031), have more co-morbidities (p=0.049), and were more likely to be anaemic (p=0.004). These results are summarised in Table 3.

Anaemic patients were more likely to be older (p=0.023), require a walking aid (p=0.030), have an increased number of conditions (p=0.045) and be diabetic (p=0.007). They also reported reduced activity levels (0.008) and were more likely to fail the walk speed test (p=0.005). Those with anaemia

were less likely to undergo an open/ hybrid reinterventions within 90 days (p=0.046), but more likely to undergo minor foot debridement (p=0.027). Table 4 summarises these findings.

Simple univariate linear regression was performed to see if there was a direct correlation between haemoglobin and grip strength. The model was statistically significant when compared to the null model, F(1, 76) = 10.61, p-value: 0.002, R2: 0.123. Figure 3 shows a scatterplot demonstrating this relationship.

There were no associations between frailty or sarcopenia with survival, amputation, reintervention or readmission. Supplementary tables 1 and 2 summarise the relationships between walk speed test failure and self-reported low activity, against other characteristics.

Discussion

This is a UK first prospective observational study performed to describe the prevalence of frailty, sarcopenia, multimorbidity and polypharmacy in the CLTI and PAD population. We have also shown that there is a relationship between frailty and sarcopenia among CLTI patients, along with a relationship between anaemia and sarcopenia.

The finding of high rates of these conditions are unsurprising. The claudication symptoms that often precede CLTI can limit activity levels and by the time patients present with rest pain or tissue loss, this insidious reduction in activity may have led to loss of independence and functional muscle loss. Indeed, this is in keeping with the literature in the UK (a recent retrospective study has shown that 52% of patients were frail by the Rockwood CFS[19]), and a meta-analysis of global literature has suggested that 49% of those with PAD are frail, although this study was limited due to significant study heterogeneity.[20]

The description of anaemia and its relationship with sarcopenia by grip strength is a new finding in the UK CLTI population, however, it has been previously described in other populations, particularly in East Asia.[21–23] Both anaemia and sarcopenia have been suggested to contribute to poor outcomes

after vascular surgery,[11,13] however, the finding that there is an association raises the possibility of a negative synergistic effect of both conditions existing in tandem. There is probably an element of mixed anaemia in this patient cohort, but there are certainly unanswered questions about the true mechanism of anaemia in this population.

Frailty and sarcopenia are both well understood to be part of aging and the concept of "inflamm-aging" has been suggested as a mechanism for this. The imbalance of pro- and anti-inflammatory processes are thought to drive this and result in inflammation mediated loss of muscle mass, and inhibition of muscle regeneration.[24] There is potential that the disease of CLTI itself, and the associated local lower limb inflammation could be further driving this inflammatory state. It could be hypothesised that this could be the case with earlier stage PAD, where the onset of claudication triggers a systemic inflammatory response. Cellular senescence and mitochondrial dysfunction have also been postulated to play a role in the pathophysiology of sarcopenia.[25]

With such high rates of frailty and sarcopenia in the vascular surgery population, it is incumbent that services take steps to manage, and where possible, rectify these conditions. The main challenge to achieve this comes down to the short timeframes required for CLTI intervention (less than 14 days as an out-patient and less than 5 days as an in-patient).[26] Complex geriatric assessment (CGA) is an increasingly used service in vascular surgery units and can be implemented via an inpatient or outpatient basis.[27–29] Indeed, the increasing use of "hot clinics" and outpatient pathways may alleviate the risk of the deconditioning that often occurs with a prolonged hospital admission.[7]

Limitations

Despite this being a UK-first, there remain some limitations of this study. Primarily, a lack of long-term follow-up limited our ability to draw conclusions regarding frailty, sarcopenia and their effect on long-term outcomes, such as amputation free survival.

In this study, there was no detectable relationship between frailty and sarcopenia against survival or other major clinical outcomes such as amputation, readmission or death. This may be because our

study cohort of 84 patients provided insufficient power to detect statistically significant rates of complications between groups. This issue was compounded by the fairly low rates of complications and death in the study, a fact that probably reflects the short follow-up time and the often-reported problem of study patients not necessarily representing the real-world population.[30]

In addition, some of the planned analyses were limited due to missing data, particularly with regard to calculation of the full Fried Frailty index and imaging metrics on skeletal muscle area. This prevented some of the analyses that were initially outlined in the protocol.[16]

Future work to address the issues raised by this study should target the multiple facets of frailty and sarcopenia. Investigation of the mechanisms of sarcopenia and its relationship with anaemia, may lead to novel findings that could provide potential targets to slow down their progression. This approach may also unveil biological processes that are unique to the pathophysiology of CLTI.

Nutritional assessment and post-operative exercise and rehabilitation programmes may help alleviate the negative consequences of frailty and sarcopenia. Correcting anaemia may also be a potential avenue, and our unit is exploring further research on this topic.

Conclusion

This prospective multi-centre study highlights the prevalence of frailty, sarcopenia and anaemia in a population with CLTI. Some important interactions are highlighted here, including the relationship between sarcopenia and anaemia. Our results suggest that a focus should be placed on managing these conditions alongside CLTI in a multidisciplinary fashion, and there is scope for further research on these conditions and their impact on outcomes and quality of life after arterial intervention.

Figures and Tables

Figure 1: Graph highlighting the prevalence of the conditions measured in the FRAILTI study

Figure 2: Flowchart showing how many patients underwent intervention for CLTI

Figure 3: Scatterplot showing relationship between haemoglobin and grip strength.

Table 1: Table showing baseline demographics, co-morbidities and social history.

Table 2: Table summarising the relationships between frailty and clinical factors.

Table 3: Table summarising the relationships between sarcopenia and clinical factors.

Table 4: Table summarising the relationships between anaemia and clinical factors.

Supplementary Table 1: Table summarising the relationships between walk speed and clinical factors.

Supplementary Table 2: Table summarising the relationships between self-reported low activity and clinical factors.

Acknowledgements

The authors of this study would like to acknowledge the involvement of the vascular research team (Samantha Mallon, Noala Parr, Esther Olabiyi and Tony Robinson), who provided invaluable assistance in the running of the study, and the clinical surgical teams in all recruitment sites, who supported recruitment to the study. In addition, we would like to recognise the contribution of the Vascular and Endovascular Research Network (VERN) for their support in running the study.

References

1. Smith GE, Long J, Wallace T, et al. Identifying the research priorities of healthcare professionals in UK vascular surgery: modified Delphi approach. BJS Open. 2020;5(2):zraa025. DOI: 10.1093/bjsopen/zraa025

2. Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and Physical Frailty: Two Sides of the Same Coin. Front Aging Neurosci [Internet]. 2014;6:192. DOI: 10.3389/fnagi.2014.00192

3. Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study. Mech Ageing Dev. 2012;133(6):456–66. DOI: 10.1016/j.mad.2012.05.005

4. Fried LP, Tangen CM, Walston J, et al. Frailty in Older Adults: Evidence for a Phenotype. J Gerontol A Biol Sci Med Sci [Internet]. 2001;56(3):M146–57. DOI: 10.1093/gerona/56.3.m146

5. Crozier-Shaw G, Joyce WP. Too frail for surgery? A frailty index in major colorectal surgery. Anz J Surg [Internet]. 2018;88:1302–5. DOI: 10.1111/ans.14792

6. Han B, Li Q, Chen X. Frailty and postoperative complications in older Chinese adults undergoing major thoracic and abdominal surgery. Clin Interv Aging. 2019;14:947–57. DOI: 10.2147/cia.s201062

7. Sivaharan A, Williams T, Ng C, et al. Ambulatory vascular clinics provide a safe and effective pathway for management of chronic limb threatening ischaemia. J Vasc Soc Gt Br Irel. 2023;2. DOI: 10.54522/jvsgbi.2023.074

8. Fernando ME, Blanchette V, Mishra R, et al. Frailty in People with Chronic Limb Threatening Ischemia and Diabetes-Related Foot Ulcers: A Systematic Review. Ann Vasc Surg. 2023;89:322–37. DOI: 10.1016/j.avsg.2022.09.057

9. Janssen I. The Epidemiology of Sarcopenia. Clin Geriatr Med [Internet]. 2011;27:355–63. DOI: 10.1016/j.cger.2011.03.004

10. Newton DH, Kim C, Lee N, Wolfe L, Pfeifer J, Amendola M. Sarcopenia predicts poor long-term survival in patients undergoing endovascular aortic aneurysm repair. J Vasc Surg. 2018;67:453–9. DOI: 10.1016/j.jvs.2017.06.092

11. Sivaharan A, Boylan L, Witham MD, Nandhra S. Sarcopenia in Patients Undergoing Lower Limb Bypass Surgery is Associated with Higher Mortality and Major Amputation Rates. Ann Vasc Surg. 2021;75:227–36. DOI: 10.1016/j.avsg.2021.02.022

12. Ramadan OI, Rosenbaum PR, Reiter JG, et al. Redefining Multimorbidity in Older Surgical Patients. J Am Coll Surg. 2023;236(5):1011–22. DOI: 10.1097/xcs.0000000000000659

13. Nandhra S, Boylan L, Prentis J, Nesbitt C. The Influence of Preoperative Anemia on Clinical Outcomes After Infrainguinal Bypass Surgery. Ann Vasc Surg. 2020; DOI: 10.1016/j.avsg.2019.11.043

14. Elm E von, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7. DOI: 10.1016/s0140-6736(07)61602-x

15. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg [Internet]. 2019;69(6):3S-125S.e40. DOI: 10.1016/j.jvs.2019.02.016

16. Hickson B, Sivaharan A, El-Sayed T, et al. The FraiLTI (Frailty in chronic Limb-Threatening Ischaemia) Protocol. J Vasc Soc Gt Br Irel. 2024;3. DOI: 10.54522/jvsgbi.2024.112

17. Steptoe A, Breeze E, Banks J, Nazroo J. Cohort Profile: The English Longitudinal Study of Ageing. Int J Epidemiology. 2013;42(6):1640–8. DOI: 10.1093/ije/dys168

18. Witham MD, Wason J, Dodds R, Sayer AA. Developing a composite outcome measure for frailty prevention trials – rationale, derivation and sample size comparison with other candidate measures. BMC Geriatr. 2020;20(1):113. DOI: 10.1186/s12877-020-1463-x

19. Houghton JS, Nickinson AT, Helm JR, et al. Associations of Clinical Frailty with Severity of Limb Threat and Outcomes in Chronic Limb-threatening Ischaemia. Ann Vasc Surg. 2021;76:406–16. DOI: 10.1016/j.avsg.2021.04.017

20. Wang Y, Wu X, Hu X, Yang Y. Prevalence of frailty in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis. Ageing Res Rev. 2022;82:101748. DOI: 10.1016/j.arr.2022.101748

21. Dai S, Wang S, He Y, Dai C, Yu J, Ma X. Association between anemia and sarcopenia among Chinese elderly: A cross-sectional study based on the China health and retirement longitudinal study. Exp Gerontol. 2023;177:112183. DOI: 10.1016/j.exger.2023.112183

22. Lee D-Y, Shin S. Sarcopenia and Anemia in Elderly Koreans: A Nationwide Population-Based Study. Healthcare. 2023;11(17):2428. DOI: 10.3390/healthcare11172428

23. Liu Q, You J, Zhong M, Wu Z, Geng Y, Huang C. Hemoglobin level is negatively associated with sarcopenia and its components in Chinese aged 60 and above. Front Public Heal. 2023;11:1081843. DOI: 10.3389/fpubh.2023.1081843

24. Franceschi C, Campisi J. Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. J Gerontol Ser A: Biomed Sci Méd Sci. 2014;69(Suppl_1):S4–9. DOI: 10.1093/gerona/glu057

25. Antuña E, Cachán-Vega C, Bermejo-Millo JC, et al. Inflammaging: Implications in Sarcopenia. Int J Mol Sci. 2022;23(23):15039. DOI: 10.3390/ijms232315039

26. Boyle JR, Atkins ER, Birmpili P, et al. A Best Practice Clinical Care Pathway for Peripheral Arterial Disease. J Vasc Soc Gt Br Irel [Internet]. 2022;1. DOI: 10.54522/jvsgbi.2022.017

27. Partridge J, Sbai M, Dhesi J. Proactive care of older people undergoing surgery. Aging Clin Exp Res. 2018;30(3):253–7. DOI: 10.1007/s40520-017-0879-4

28. Partridge JSL, Healey A, Modarai B, Harari D, Martin FC, Dhesi JK. Preoperative comprehensive geriatric assessment and optimisation prior to elective arterial vascular surgery: a health economic analysis. Age Ageing. 2021;50(5):1770–7. DOI: 10.1093/ageing/afab094

29. Partridge JSL, Harari D, Martin FC, et al. Randomized clinical trial of comprehensive geriatric assessment and optimization in vascular surgery. Brit J Surg. 2017;104(6):679–87. DOI: 10.1002/bjs.10459

30. Habibzadeh F. Disparity in the selection of patients in clinical trials. Lancet. 2022;399(10329):1048. DOI: 10.1016/s0140-6736(22)00176-3


Frailty
51.8%
Sarcopenia
33.3%
Anaemia
53.8%
Multimorbidity
67.9%
Polypharmacy
79.8%
0
10
20
30
40
50
60
70
80
90
100
Prevalance (%)


Patients with CLTI
n=84
Revascularisation?
(missing = 3)
No
Patient not revascularised
n=17
Primary amputation
n=5
Analgesia/ palliation
n=12
Yes
Patients revascularised
n=64
Open/ Hybrid
n=27
Endovascular
n=36


Grip Strength
50
40
30
20
10
90
120
150
180
Haemoglobin

Demographics	
Age	
Mean (SD)	71.464 (10.986)
Range	49.000 - 93.000
Gender	
Female	30 (35.7%)
Male	54 (64.3%)
Ethnicity (missing = 14)	
Asian	1 (1.4%)
Bangladeshi	1 (1.4%)
Black Caribbean	2 (2.9%)
Indian	2 (2.9%)
White British	64 (91.4%)
Weight	
Mean (SD)	78.827 (20.429)
Range	47.000 - 152.000
Height (missing = 1)	
Mean (SD)	169.904 (9.810)
Range	147.000 - 190.000
BMI (missing = 1)	
Mean (SD)	27.404 (6.879)
Range	18.724 - 55.831

Co-morbidities	
Ischaemic heart disease (missing = 1)	37 (44.6%)
Previous stroke/ TIA (missing = 1)	12 (14.5%)
Heart failure (missing = 1)	13 (15.7%)
Type 2 diabetes (missing = 1)	43 (51.8%)
Atrial Fibrillation (missing = 1)	16 (19.3%)
Hypothyroidism (missing = 1)	10 (12.0%)
Dementia (missing = 2)	0 (0.0%)
Anxiety (missing = 2)	7 (8.5%)
Depression (missing = 3)	8 (9.9%)
Parkinsons (missing = 2)	1 (1.2%)
Chronic obstructive pulmonary disease (missing = 2)	22 (26.8%)
Asthma (missing = 2)	5 (6.1%)
Other lung conditions (missing = 1)	4 (4.8%)
Osteoarthritis (missing = 2)	23 (28.0%)
Inflammatory arthropathy (missing = 3)	5 (6.2%)
Smoking status (missing = 1)	
Current smoker	20 (24.1%)
Ex-smoker (for longer than 2 months)	36 (43.4%)
Ex-smoker (for shorter than 2 months)	11 (13.3%)
Never smoker	16 (19.3%)
Alcohol intake (missing = 4)	
0 drinks daily	57 (71.2%)
1-2 drinks daily	15 (18.8%)
3-4 drinks daily	6 (7.5%)
5+ drinks daily	2 (2.5%)
Living circumstances	
Bungalow	17 (20.2%)
Flat	12 (14.3%)
House	51 (60.7%)
Other	3 (3.6%)
Residential Care	1 (1.2%)

Clinical Frailty scale (missing = 1)	Not Frail (N=40)	Frail (N=43)	p value
Age			0.330
Mean (SD)	70.475 (9.969)	72.814 (11.632)	
Range	52.000 - 88.000	49.000 - 93.000	
Gender			0.106
Female	10 (25.0%)	19 (44.2%)	
Male	30 (75.0%)	24 (55.8%)	
Smoking Status			0.467
Current Smoker	11 (27.5%)	9 (20.9%)	
Ex-smoker >2 months	17 (42.5%)	19 (44.2%)	
Ex-smoker <2 months	3 (7.5%)	8 (18.6%)	
Never smoker	9 (22.5%)	7 (16.3%)	
Walking Aid			**< 0.001*** **
Required walking aid	20 (50.0%)	37 (86.0%)	
Medications			
Number of medications (missing = 7)			**0.027***
Mean (SD)	8.222 (3.490)	10.000 (3.762)	
Range	2.000 - 15.000	2.000 - 15.000	
Polypharmacy	31 (77.5%)	36 (83.7%)	0.581
Excessive Polypharmacy	14 (35.0%)	22 (51.2%)	0.184
Co-morbidities			
Number of conditions			**0.002** **
Mean (SD)	1.800 (1.114)	3.116 (1.880)	
Range	0.000 - 4.000	0.000 - 7.000	
Multimorbidity	24 (60.0%)	33 (76.7%)	0.155
Diabetes Mellitus	15 (37.5%)	28 (65.1%)	**0.016***
Anaemia	17 (43.6%)	26 (63.4%)	0.116
Sarcopenic (grip strength)	8 (20.0%)	19 (46.3%)	**0.018***
Walk speed test failure	10 (25.0%)	21 (48.8%)	**0.040***
Low Activity	17 (42.5%)	39 (90.7%)	**<0.001*** **
Revascularisation			
Revascularisation performed	33 (84.6%)	31 (73.8%)	0.282
Type of revascularisation (missing = 20)			0.203
Endovascular	16 (48.5%)	20 (66.7%)	
Open or Hybrid	17 (51.5%)	10 (33.3%)	
Complications (missing = 2)			
Cardiac (MACE)	0 (0.0%)	3 (7.1%)	0.242

Respiratory	0 (0.0%)	2 (4.8%)	0.494
Wound	1 (2.6%)	4 (9.5%)	0.361
Urinary	0 (0.0%)	0 (0.0%)	NA
Ipsilateral limb loss	1 (2.6%)	1 (2.4%)	1.000
Ipsilateral limb complication	2 (5.1%)	2 (4.8%)	1.000
MALE	3 (7.7%)	3 (7.1%)	1.000
Readmissions and reinterventions			
Number of readmission (missing = 9)			0.143
0	24 (66.7%)	21 (55.3%)	
1	9 (25.0%)	10 (26.3%)	
2	1 (2.8%)	5 (13.2%)	
3	2 (5.6%)	0 (0.0%)	
4	0 (0.0%)	2 (5.3%)	
Reintervention (Open or hybrid) (missing = 2)	3 (7.7%)	1 (2.4%)	0.347
Reintervention (Endovascular) (missing = 2)	1 (2.6%)	5 (11.9%)	0.203
Reintervention (Wound debridement) (missing = 2)	1 (2.6%)	1 (2.4%)	1.000
Reintervention (Foot debridement) (missing = 2)	4 (10.3%)	2 (4.8%)	0.421

Sarcopenia – grip strength (missing = 3)	**Not sarcopenic (N=54)**	**Sarcopenic (N=27)**	**p value**
Age			**0.031***
Mean (SD)	69.556 (10.511)	75.037 (10.675)	
Range	50.000 - 90.000	49.000 - 93.000	
Gender			0.220
Female	16 (29.6%)	12 (44.4%)	
Male	38 (70.4%)	15 (55.6%)	
Smoking Status			0.986
Current Smoker	13 (24.1%)	7 (25.9%)	
Ex-smoker >2 months	22 (40.7%)	12 (44.4%)	
Ex-smoker <2 months	8 (14.8%)	3 (11.1%)	
Never smoker	11 (20.4%)	5 (18.5%)	
Walking Aid			0.080
Required walking aid	21 (38.9%)	5 (18.5%)	
Medications			
Number of medications (missing = 6)			0.299
Mean (SD)	8.780 (3.705)	9.680 (3.637)	
Range	2.000 - 15.000	3.000 - 15.000	
Polypharmacy	43 (79.6%)	23 (85.2%)	0.763
Excessive Polypharmacy	22 (40.7%)	13 (48.1%)	0.635
Co-morbidities			
Number of conditions			**0.049***
Mean (SD)	2.204 (1.653)	2.889 (1.601)	
Range	0.000 - 7.000	0.000 - 6.000	
Multimorbidity	34 (63.0%)	21 (77.8%)	0.214
Diabetes Mellitus	26 (48.1%)	15 (55.6%)	0.639
Anaemia	21 (41.2%)	21 (77.8%)	**0.004****
Walk speed test failure	16 (29.6%)	13 (48.1%)	0.140
Low Activity	32 (59.3%)	22 (81.5%)	0.051
Revascularisation			
Revascularisation performed	41 (75.9%)	22 (88.0%)	0.248
Type of revascularisation (missing = 19)			0.110
Endovascular	20 (48.8%)	15 (71.4%)	
Open or Hybrid	21 (51.2%)	6 (28.6%)	
Complications (missing = 2)			
Cardiac (MACE)	2 (3.7%)	1 (4.0%)	1.000
Respiratory	2 (3.7%)	0 (0.0%)	1.000
Wound	3 (5.6%)	2 (8.0%)	0.649
Urinary	0 (0.0%)	0 (0.0%)	NA
Ipsilateral limb loss	1 (1.9%)	1 (4.0%)	0.536
Ipsilateral limb complication	3 (5.6%)	1 (4.0%)	1.000
MALE	4 (7.4%)	2 (8.0%)	1.000
Readmissions and reinterventions			
Number of readmission (missing = 7)			0.270
0	31 (62.0%)	14 (58.3%)	
1	13 (26.0%)	6 (25.0%)	
2	4 (8.0%)	2 (8.3%)	
3	2 (4.0%)	0 (0.0%)	
4	0 (0.0%)	2 (8.3%)	
Reintervention (Open or hybrid) (missing = 2)	4 (7.4%)	0 (0.0%)	0.302
Reintervention (Endovascular) (missing = 2)	2 (3.7%)	4 (16.0%)	0.076
Reintervention (Wound debridement)	1 (1.9%)	1 (4.0%)	0.536

(missing = 2)			
Reintervention (Foot debridement) (missing = 2)	3 (5.6%)	3 (12.0%)	0.374

Anaemia (missing = 4)	**Not anaemic (N=37)**	**Anaemic (N=43)**	**p value**
Age			**0.023***
Mean (SD)	68.703 (9.941)	74.186 (11.042)	
Range	50.000 – 90.000	49.000 – 93.000	
Gender			1.000
Female	12 (32.4%)	15 (34.9%)	
Male	25 (67.6%)	28 (65.1%)	
Smoking Status			0.210
Current Smoker	10 (27.0%)	9 (20.9%)	
Ex-smoker >2 months	16 (43.2%)	18 (41.9%)	
Ex-smoker <2 months	7 (18.9%)	4 (9.3%)	
Never smoker	4 (10.8%)	12 (27.9%)	
Walking Aid			**0.030***
Required walking aid	17 (45.9%)	9 (20.9%)	
Medications			
Number of medications (missing = 7)			0.275
Mean (SD)	8.576 (3.606)	9.475 (3.748)	
Range	2.000 - 15.000	2.000 - 15.000	
Polypharmacy	28 (75.7%)	36 (83.7%)	0.412
Excessive Polypharmacy	14 (37.8%)	20 (46.5%)	0.500
Co-morbidities			
Number of conditions			**0.045***
Mean (SD)	2.054 (1.615)	2.767 (1.631)	
Range	0.000 - 6.000	0.000 - 7.000	
Multimorbidity	22 (59.5%)	33 (76.7%)	0.146
Diabetes Mellitus	13 (35.1%)	29 (67.4%)	**0.007****
Walk speed test failure	8 (21.6%)	23 (53.5%)	**0.005****
Low Activity	19 (51.4%)	35 (81.4%)	**0.008****
Revascularisation			
Revascularisation performed (missing = 2)	31 (83.8%)	31 (75.6%)	0.413
Type of revascularisation (missing = 19)			**0.004****
Endovascular	12 (38.7%)	23 (76.7%)	
Open or Hybrid	19 (61.3%)	7 (23.3%)	
Complications (missing = 2)			
Cardiac (MACE)	2 (5.4%)	1 (2.4%)	0.601
Respiratory	2 (5.4%)	0 (0.0%)	0.222
Wound	3 (8.1%)	1 (2.4%)	0.341
Urinary	0 (0.0%)	0 (0.0%)	NA
Ipsilateral limb loss	0 (0.0%)	2 (4.9%)	0.495
Ipsilateral limb complication	2 (5.4%)	2 (4.9%)	1.000
MALE	2 (5.4%)	4 (9.8%)	0.678
Readmissions and reinterventions			
Number of readmission (missing = 9)			0.547
0	21 (60.0%)	22 (61.1%)	
1	10 (28.6%)	9 (25.0%)	
2	3 (8.6%)	3 (8.3%)	
3	1 (2.9%)	0 (0.0%)	
4	0 (0.0%)	2 (5.6%)	
Reintervention (Open or hybrid) (missing = 2)	4 (10.8%)	0 (0.0%)	**0.046***
Reintervention (Endovascular) (missing = 2)	2 (5.4%)	4 (9.8%)	0.678
Reintervention (Wound debridement) (missing = 2)	0 (0.0%)	1 (2.4%)	1.000
Reintervention (Foot debridement) (missing = 2)	0 (0.0%)	6 (14.6%)	**0.027***